BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17169788)

  • 1. Dysregulated EVI1 expression in myeloid malignancies.
    Pardanani A
    Leuk Lymphoma; 2006 Dec; 47(12):2443-4. PubMed ID: 17169788
    [No Abstract]   [Full Text] [Related]  

  • 2. Reverse transcriptase-polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemia.
    Weisser M; Kern W; Schoch C; Tschulik C; Hiddemann W; Haferlach T; Schnittger S
    Leuk Lymphoma; 2006 Dec; 47(12):2645-7. PubMed ID: 17169810
    [No Abstract]   [Full Text] [Related]  

  • 3. Genomic dark matter sheds light on EVI1-driven leukemia.
    Koche RP; Armstrong SA
    Cancer Cell; 2014 Apr; 25(4):407-8. PubMed ID: 24735919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
    Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G
    Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression.
    Ohyashiki JH; Ohyashiki K; Shimamoto T; Kawakubo K; Fujimura T; Nakazawa S; Toyama K
    Blood; 1995 Jun; 85(12):3713-8. PubMed ID: 7780155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
    Haas K; Kundi M; Sperr WR; Esterbauer H; Ludwig WD; Ratei R; Koller E; Gruener H; Sauerland C; Fonatsch C; Valent P; Wieser R
    Genes Chromosomes Cancer; 2008 Apr; 47(4):288-98. PubMed ID: 18181178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genes break barrier between MDS and AML.
    Haferlach C
    Blood; 2015 Jan; 125(1):9-10. PubMed ID: 25554745
    [No Abstract]   [Full Text] [Related]  

  • 8. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.
    Gröschel S; Sanders MA; Hoogenboezem R; de Wit E; Bouwman BAM; Erpelinck C; van der Velden VHJ; Havermans M; Avellino R; van Lom K; Rombouts EJ; van Duin M; Döhner K; Beverloo HB; Bradner JE; Döhner H; Löwenberg B; Valk PJM; Bindels EMJ; de Laat W; Delwel R
    Cell; 2014 Apr; 157(2):369-381. PubMed ID: 24703711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
    Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
    Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced expression of the EVI1 gene in NUP98/HOXA-expressing leukemia cells.
    Eguchi-Ishimae M; Eguchi M; Ohyashiki K; Yamagata T; Mitani K
    Int J Hematol; 2009 Mar; 89(2):253-256. PubMed ID: 19241117
    [No Abstract]   [Full Text] [Related]  

  • 11. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
    Lugthart S; van Drunen E; van Norden Y; van Hoven A; Erpelinck CA; Valk PJ; Beverloo HB; Löwenberg B; Delwel R
    Blood; 2008 Apr; 111(8):4329-37. PubMed ID: 18272813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.
    Vázquez I; Maicas M; Cervera J; Agirre X; Marin-Béjar O; Marcotegui N; Vicente C; Lahortiga I; Gomez-Benito M; Carranza C; Valencia A; Brunet S; Lumbreras E; Prosper F; Gómez-Casares MT; Hernández-Rivas JM; Calasanz MJ; Sanz MA; Sierra J; Odero MD
    Haematologica; 2011 Oct; 96(10):1448-56. PubMed ID: 21750091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
    Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; van Putten WL; Valk PJ; van der Poel-van de Luytgaarde S; Hack R; Slater R; Smit EM; Beverloo HB; Verhoef G; Verdonck LF; Ossenkoppele GJ; Sonneveld P; de Greef GE; Löwenberg B; Delwel R
    Blood; 2003 Feb; 101(3):837-45. PubMed ID: 12393383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2).
    Wang HY; Rashidi HH
    Arch Pathol Lab Med; 2016 Dec; 140(12):1404-1410. PubMed ID: 27628325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells.
    Mochizuki N; Shimizu S; Nagasawa T; Tanaka H; Taniwaki M; Yokota J; Morishita K
    Blood; 2000 Nov; 96(9):3209-14. PubMed ID: 11050005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations.
    Russell M; List A; Greenberg P; Woodward S; Glinsmann B; Parganas E; Ihle J; Taetle R
    Blood; 1994 Aug; 84(4):1243-8. PubMed ID: 8049440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements.
    Sitailo S; Sood R; Barton K; Nucifora G
    Leukemia; 1999 Nov; 13(11):1639-45. PubMed ID: 10557037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions.
    Wieser R
    Gene; 2007 Jul; 396(2):346-57. PubMed ID: 17507183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breakpoint analysis by fluorescence in situ hybridization in myelodysplastic syndromes with t(3;12)(q26;p13) and expression of EVI1.
    van de Loosdrecht AA; Kok K; de Vries B; van der Veen AY; van den Berg E; Esselink MT; Marynen P; Vellenga E; van Imhoff GW
    Leukemia; 2000 Oct; 14(10):1857-8. PubMed ID: 11021761
    [No Abstract]   [Full Text] [Related]  

  • 20. Improved classification of MLL-AF9-positive acute myeloid leukemia patients based on BRE and EVI1 expression.
    Noordermeer SM; Monteferrario D; Sanders MA; Bullinger L; Jansen JH; van der Reijden BA
    Blood; 2012 May; 119(18):4335-7. PubMed ID: 22555662
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.